ValiRx Plc (VAL):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:ValiRx Plc (VAL) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7347
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2, and NAV3 cancer screening test. It uses GeneICE technology, which enables silencing of specific genes by targeted histone deacetylation for chromatin condensation. ValiRx’s ValiMedix division sells and distributes oncology therapeutics. The company’s ValiPharma division is a therapeutics division that provides technologies for the treatment of cancer. Its’s ValiFinn division offers research and development services. The company also develops clinical trials, which is used to treat hormone induced refractory prostate cancer and other conditions of hormone. ValiRx is headquartered in London, the UK.

ValiRx Plc (VAL) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ValiRx Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
ValiRx Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
ValiRx Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
ValiRx Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
ValiRx Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
ValiRx Plc, Medical Equipment, Deal Details 10
Asset Purchase 10
ValiRx Acquires Biomarkers Business Unit From Pharmatest Services For US$0.2 Million 10
Equity Offering 12
ValiRx Raises USD1.5 Million in Private Placement of Shares 12
ValiRx Raises USD1.33 Million in Private Placement of Shares 13
ValiRx Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 14
ValiRx Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 15
ValiRx Raises USD0.7 Million in Private Placement of Shares 16
Valirx Raises Funds in Private Placement of Shares 17
Valirx Raises USD1.4 Million in Private Placement of Shares 18
Valirx Raises USD1.58 Million in Placing of Ordinary Shares 19
Acquisition 20
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 20
ValiRx Plc – Key Competitors 21
ValiRx Plc – Key Employees 22
ValiRx Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Joint Venture 23
Recent Developments 24
Financial Announcements 24
Sep 25, 2018: VALIRX: Half yearly report for the period ended 30 June 2018 24
Apr 10, 2018: ValiRx: Final Results for the Year Ended 31 December 2017 26
Sep 26, 2017: Valirx: Half Yearly Report For The Period Ended 30 June 2017 30
May 05, 2017: ValiRx: Final Results for the Year Ended 31 December 2016 32
Legal and Regulatory 35
Apr 18, 2017: ValiRx: Change of Registered Office 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
ValiRx Plc, Medical Equipment, Key Facts, 2017 2
ValiRx Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
ValiRx Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
ValiRx Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
ValiRx Plc, Deals By Market, 2012 to YTD 2018 8
ValiRx Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
ValiRx Acquires Biomarkers Business Unit From Pharmatest Services For US$0.2 Million 10
ValiRx Raises USD1.5 Million in Private Placement of Shares 12
ValiRx Raises USD1.33 Million in Private Placement of Shares 13
ValiRx Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 14
ValiRx Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 15
ValiRx Raises USD0.7 Million in Private Placement of Shares 16
Valirx Raises Funds in Private Placement of Shares 17
Valirx Raises USD1.4 Million in Private Placement of Shares 18
Valirx Raises USD1.58 Million in Placing of Ordinary Shares 19
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 20
ValiRx Plc, Key Competitors 21
ValiRx Plc, Key Employees 22
ValiRx Plc, Subsidiaries 23
ValiRx Plc, Joint Venture 23

List of Figures
ValiRx Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
ValiRx Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
ValiRx Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
ValiRx Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[ValiRx Plc (VAL):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Deutsche Borse AG:企業のM&A・事業提携・投資動向
    Deutsche Borse AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Deutsche Borse AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Power Finance Corporation Ltd.:企業の戦略・SWOT・財務情報
    Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Mitsubishi Chemical Corp:企業の戦略的SWOT分析
    Mitsubishi Chemical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Sierra Nevada Corporation:企業の戦略・SWOT・財務情報
    Sierra Nevada Corporation - Strategy, SWOT and Corporate Finance Report Summary Sierra Nevada Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Epcor Utilities Inc:企業の発電所・SWOT分析2018
    Epcor Utilities Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • AddLife AB (ALIF B):医療機器:M&Aディール及び事業提携情報
    Summary AddLife AB (AddLife) is a medical device company. The company operates in business areas such as Labtech and Medtech. Its Labtech business offers products in various categories including hematology, pathology, POC, cellular biology, analytical instruments, consumables, advanced instruments, …
  • Expedia Inc:企業のM&A・事業提携・投資動向
    Expedia Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Expedia Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Loral Space & Communications Inc. (LORL):企業の財務・戦略的SWOT分析
    Loral Space & Communications Inc. (LORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Isovolta AG:企業の戦略的SWOT分析
    Isovolta AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Defence Research and Development Organisation:企業の戦略・SWOT・財務情報
    Defence Research and Development Organisation - Strategy, SWOT and Corporate Finance Report Summary Defence Research and Development Organisation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • AgeneBio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary AgeneBio Inc (AgeneBio) is a pharmaceutical company that develops therapies for psychiatric and neurological diseases. The company’s therapy is targeted to prevent neurodegeneration and preserve and restore cognitive function for unserved patients. Its lead candidate AGB101 is under phase 3 …
  • Misr Hotels Co:企業の戦略・SWOT・財務分析
    Misr Hotels Co - Strategy, SWOT and Corporate Finance Report Summary Misr Hotels Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Magnetek Inc:企業の戦略的SWOT分析
    Magnetek Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • San Diego Gas & Electric Co:電力:M&Aディール及び事業提携情報
    Summary San Diego Gas & Electric Company (SDGE), a subsidiary of Sempra Energy is an energy service provider that offers electric generation, transmission and distribution services. The company also distributes natural gas. Its residential services include payment and bill assistance, start, stop, m …
  • Blaze Bioscience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Blaze Bioscience Inc (Blaze) is a biotechnology company that offers guided cancer therapy solutions. The company develops tumor paint products and optide-based guided cancer therapeutics. It provides cancer surgery by development of real-time, high-resolution view of cancer cell technologies …
  • Advance Synergy Berhad:企業の戦略・SWOT・財務情報
    Advance Synergy Berhad - Strategy, SWOT and Corporate Finance Report Summary Advance Synergy Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CMIC Holdings Co Ltd (2309):企業の財務・戦略的SWOT分析
    Summary CMIC Holdings Co Ltd (CMIC) is a contract research organization that supports drug development services. The organization offers medical research related services to pharmaceuticals and medical organizations. Its CRO business services include monitoring, data management, STAT analysis, regis …
  • Rockwool International AS:戦略・SWOT・企業財務分析
    Rockwool International AS - Strategy, SWOT and Corporate Finance Report Summary Rockwool International AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • WellCare Health Plans, Inc.:企業の戦略・SWOT・財務情報
    WellCare Health Plans, Inc. - Strategy, SWOT and Corporate Finance Report Summary WellCare Health Plans, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Egalet Corp (EGLT):製薬・医療:M&Aディール及び事業提携情報
    Summary Egalet Corp (Egalet) is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for pain and other conditions. Its product portfolio includes OXAYDO (oxycodone HCl, USP) tablets CII for the management of acute and chronic moderate to severe pain; SP …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆